NRG Therapeutics
NRG Therapeutics is a clinical-stage neuroscience company developing small molecule inhibitors of the mitochondrial permeability transition pore as disease-modifying treatments for neurodegenerative disorders.
Its lead candidate, NRG5051, entered Phase 1 clinical trials in January 2026 for ALS and Parkinson's disease.
The company has raised over £75 million in equity and grant funding from investors including the Dementia Discovery Fund, M Ventures, Novartis Venture Fund and Parkinson's UK.
Latest News
NRG Therapeutics Starts PET Biodistribution Trial of NRG5051
NRG Therapeutics has started a PET imaging trial in healthy volunteers in London to confirm that NRG5051, its mitochondrial permeability transition pore inhibitor, reaches the brain and to inform dosing for patient studies. The trial runs alongside an ongoing Phase 1 study, with a Phase 2 proof-of-concept trial in ALS planned for 2027.
NRG Therapeutics Appoints Claus Sundgreen as Chief Medical Officer
NRG Therapeutics has appointed Dr Claus Sundgreen as Chief Medical Officer, effective 1 August 2026. Sundgreen, a neuroscience drug development specialist with particular expertise in ALS, will lead clinical strategy for lead candidate NRG5051, including its ongoing Phase 1 trial and a planned Phase 2 ALS study starting in 2027.